An interventional study of Interdisciplinary intervention and Standard rehabilitation program in Neurodevelopmental Disorder (Diagnosis), Feeding Disorder and ARFID, sponsored by IRCCS San Raffaele Roma. Completed at 1 site in Italy. Open to participants aged 2 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by IRCCS San Raffaele Roma · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Neurodevelopmental Disorders with a site in Italy — 18 open to participants now, 24 under way, 6 of them phase 3. Neurodevelopmental Disorders · Italy.
Among the 35 studies in Neurodevelopmental Disorders with a site in Italy, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, and was the 31st registered.
355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.
Browse Neurodevelopmental Disorders studies →18 of the 35 studies in Neurodevelopmental Disorders with a site in Italy are open now. Recruiting first, the newest first:
GRIN Therapeutics, Inc. · Sites in Italy, United States, Australia and 10 more countries
Ages 1 mo–18 yrs
Meyer Children's Hospital IRCCS · Sites in Italy, France, Poland
Ages 2–30
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 8–18
Istituto Giannina Gaslini · Sites in Italy
Ages 28 days+
IRCCS Eugenio Medea · Sites in Italy
Ages 2+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: 2 Years to 7 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 86 across 218 interventional studies indexed under Neurodevelopmental Disorders.
Median enrollment 80 across the 25 interventional studies, 139 across the 10 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 35 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele Roma is the lead sponsor of 71 studies on the registry; 25 are open to participants now.
IRCCS San Raffaele Roma has 1 study filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Neurodevelopmental Disorders with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT06851377IRCCS Eugenio MedeaExpanding NGS Data with Optical Genome Mapping (OGM) | 2026-12 |
| NCT07884227Istituto Giannina GasliniMulti-Omics Genetic Investigation Strategies to Enhance the Diagnostic Workflow for Rare Diseases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 35 studies in Neurodevelopmental Disorders with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pediatric Feeding Disorders (PFDs) are conditions characterized by persistent difficulties in food intake, commonly manifesting as food selectivity, food refusal, and dysfunctional mealtime behaviors. Their prevalence in the general pediatric population ranges from 3% to 10%, with substantially higher rates reported among children with neurodevelopmental disorders. The impact of PFDs extends beyond growth and nutritional status, affecting cognitive and emotional development as well as the well-being of the entire family system. Although several treatment models have been proposed, scientific evidence supporting outpatient interventions remains limited and Italy-specific studies are lacking. Moreover, despite the availability of standardized assessment tools, feeding-related outcomes are not yet systematically addressed within outpatient clinical practice for children with neurodevelopmental disorders.
The present study aims to evaluate whether an interdisciplinary intervention protocol involving a psychologist, a speech and language therapist (SLP), and a Neuro and Psychomotor Therapist of Developmental Age (TNPEE) can improve food variety and reduce dysfunctional mealtime behaviors in this population. The study is designed as a pilot randomized controlled trial developed across five sequential phases: participant enrollment and screening using the Montreal Children's Hospital Feeding Scale (MCH-FS); baseline standardized assessment (T0) using the Pediatric Eating Assessment Tool (PediEAT) and the Short Sensory Profile (SSP); random allocation of participants to an experimental group or a control group; delivery of the interdisciplinary intervention exclusively to the experimental group; and a final standardized assessment conducted six weeks later (T1) to evaluate changes over time and between groups.
This pilot study primarily aims to assess feasibility and to estimate the variability of outcome measures; therefore, no formal sample size or power calculation was performed. The planned enrollment of 12 participants per group was determined based on feasibility considerations and in line with CONSORT recommendations for pilot trials. The proposed protocol seeks to address current gaps in the literature by systematically targeting feeding-related outcomes through an explicitly interdisciplinary approach that integrates psychological, speech and language, and neuropsychomotor perspectives in the management of PFD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Interdisciplinary intervention
Other: Standard rehabilitation program
Each patient undergoes 12 individual therapy sessions (twice weekly over 6 consecutive weeks), each lasting 45 minutes. Sessions are conducted by a psychologist, who provides parent training, and by a speech-language pathologist (SLP) and a Neuro and Psychomotor Therapist of Developmental Age (TNPEE), who deliver direct intervention to the child in the presence of the caregiver. The psychologist establishes a feeding routine and educates the caregiver on emotional and behavioral management during mealtimes. The SLP and TNPEE implement play-based sensory activities and a specific exercise protocol to enhance oral sensitivity and strengthen orofacial musculature. From the second session onward, the food diary is monitored and caregivers receive guidance for the gradual introduction of new foods at home. At each session, the interdisciplinary team monitors progress based on food diary data and caregiver reports and adapts the intervention to the child's needs.
Participants in the control group receive standard multidisciplinary rehabilitation as provided in an ex art. 26 accredited rehabilitation center. The rehabilitation program includes speech and language therapy, neuro and psychomotor therapy (TNPEE), physiotherapy, and psychological support, delivered according to an individualized rehabilitation plan. Treatments are provided by licensed therapists in accordance with routine clinical practice.The frequency and duration of each intervention are defined by the individualized rehabilitation plan and reflect standard clinical practice.
Pediatric Eating Assessment Tool (PediEAT) Total Score
The Pediatric Eating Assessment Tool (PediEAT) is a standardized parent-report questionnaire consisting of 78 items assessing observable feeding-related symptoms in children aged 6 months to 7 years. Each item is rated on a 6-point Likert scale (0 to 5). The total score ranges from 0 to 390, with higher scores indicating greater feeding-related concern (worse outcome).
Time frame: Baseline and immediately post-intervention (6 weeks)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Sep 2026, 8 months.
Of 142 non-industry interventional studies with no phase under Neurodevelopmental Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 8 months is below that.
Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 15 and three quarters within 52.
Primary completion moved twice since we started tracking on Sep 25, 2026: Feb 2026 → Sep 2026, last on Nov 6, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Feb 2026 → Oct 2026, last on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →
IRCCS San Raffaele Roma